Ignite Creation Date:
2024-05-06 @ 3:23 PM
Last Modification Date:
2024-10-26 @ 1:48 PM
Study NCT ID:
NCT04614467
Status:
TERMINATED
Last Update Posted:
2023-10-17
First Post:
2020-10-29
Brief Title:
A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular Dysfunction
Sponsor:
Lisata Therapeutics Inc
Organization:
Lisata Therapeutics Inc
Study Overview
Official Title:
A Double-Blind Randomized Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of CLBS16 in Subjects With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery Disease
Status:
TERMINATED
Status Verified Date:
2023-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Sponsor decision
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
FREEDOM
Brief Summary:
This clinical trial will explore the efficacy and safety of GCSF-mobilized autologous CD34 cells for the treatment of CMD in adults currently experiencing angina and with no obstructive coronary artery disease Eligible subjects will receive a single administration of CLBS16 or placebo
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None